Ocugen OCGN is making rapid progress in its gene therapy programs for retinal diseases, which have differentiated mechanisms ...

The average one-year price target for Ocugen (NasdaqCM:OCGN) has been revised to $8.36 / share. This is an increase of 26.15% from the prior estimate of $6.63 dated September 27, 2025. The price ...

The future may be looking up for Ocugen (OCGN) stock after the biotech company announced a change in leadership. Ramesh Ramachandran will take over as the company’s new principal financial officer and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Ocugen (NASDAQ:OCGN) stock fans will want to keep an eye on the clinical-stage biopharmaceutical company as it has big news coming on Wednesday. That’s when Ocugen plans to hold a clinical showcase ...

Ocugen, Inc. (NASDAQ:OCGN) shares are trading higher Friday after the company announced it has received approval to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of its ...

In the fourth quarter of 2025, Ocugen ’s Board, following a review by its Compensation Committee and external consultant, approved an additional grant of 9,369,604 performance restricted stock units ...